The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mallela Venkataramna Reddy
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals informed BSE that Mallela Venkataramna Reddy, a non-promoter, was allotted 3,30,000 equity shares on 12 February 2026 through a preferential allotment, representing 1.66% of the allotted share base. His stake in the company rose from 15,00,000 shares (8.52% of pre-allotment capital, 6.01% on diluted basis) to 18,30,000 shares (9.18% on expanded capital, 6.71% on diluted basis). The company's total equity share capital expanded from Rs 1.76 crore (17.615 lakh shares of Rs 10 each) to Rs 1.99 crore (19.935 lakh shares), with an additional 73.35 lakh convertible warrants outstanding on a fully diluted basis.
This is a non-promoter receiving new shares via preferential allotment, not an open-market purchase, so existing shareholders face only minor dilution. The acquirer's holding remains below 10% of total capital and well under takeover-trigger thresholds, so no control implications are expected.